Image
|
Figure Caption
Fig. S2
Requirement of tracrRNA and crRNA for Cas9-mediated genome modifications.
(A, E) an uninjected embryo. (B, F) Tg(cmlc2:EGFP)-derived embryos injected with Cas9 protein (400 pg). (C, G) Tg(cmlc2:EGFP)-derived embryos injected with Cas9 mRNA (250 pg). (D, H) Tg(cmlc2:EGFP)-derived embryos injected with two crRNAs (spns2-crRNA; 25 pg + tyr-crRNA; 25 pg) and tracrRNA (100 pg). No abnormality in cardiac development at 1 dpf or the retinal epithelium pigmentation at 2 dpf was observed.
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ PLoS One